Technical Analysis for FENC - Fennec Pharmaceuticals Inc.

Grade Last Price % Change Price Change
B 11.07 11.37% 1.13
FENC closed up 11.37 percent on Monday, March 18, 2024, on 4.62 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Mar 28
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Expansion Breakout Bullish Swing Setup 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
50 DMA Support Bullish 11.37%
Volume Surge Other 11.37%
Multiple of Ten Bearish Other 11.37%

   Recent Intraday Alerts

Alert Time
Possible Pocket Pivot about 11 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Gapped Up (Full) about 12 hours ago
Rose Above Previous Day's High about 12 hours ago
Rose Above Upper Bollinger Band about 12 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fennec Pharmaceuticals Inc. Description

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Oncology Blastoma Hearing Sarcoma Brain Tumor Cancer Therapeutics Childhood Neuroblastoma Neoplasms Hearing Loss Localized Tumors Osteosarcoma

Is FENC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.92
52 Week Low 6.3
Average Volume 96,894
200-Day Moving Average 8.74
50-Day Moving Average 9.84
20-Day Moving Average 9.57
10-Day Moving Average 9.87
Average True Range 0.46
RSI (14) 72.14
ADX 19.47
+DI 38.50
-DI 10.87
Chandelier Exit (Long, 3 ATRs) 10.04
Chandelier Exit (Short, 3 ATRs) 9.98
Upper Bollinger Bands 10.55
Lower Bollinger Band 8.58
Percent B (%b) 1.26
BandWidth 20.57
MACD Line 0.15
MACD Signal Line 0.01
MACD Histogram 0.1476
Fundamentals Value
Market Cap 295.67 Million
Num Shares 26.7 Million
EPS -0.75
Price-to-Earnings (P/E) Ratio -14.76
Price-to-Sales 20.81
Price-to-Book 84.82
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.27
Resistance 3 (R3) 12.26 11.85 12.07
Resistance 2 (R2) 11.85 11.54 11.85 12.00
Resistance 1 (R1) 11.46 11.35 11.65 11.47 11.94
Pivot Point 11.04 11.04 11.14 11.05 11.04
Support 1 (S1) 10.66 10.74 10.85 10.67 10.20
Support 2 (S2) 10.24 10.55 10.25 10.14
Support 3 (S3) 9.85 10.24 10.07
Support 4 (S4) 9.87